Luis Miguel Pérez-Belmonte

11PUBLICATIONS
17CO-AUTHORS
PharmacogenomicsEnvironmental epidemiologyEpidemiological modellingMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jun 26, 2026
Clinical Effectiveness and Safety of Oral Semaglutide in a Real-World Cohort of Patients with Heart Failure with Reduced Ejection Fraction, Type 2 Diabetes and Obesity: A Propensity Score-Matched Analysis.

|May 04, 2026
Once-Weekly Semaglutide in Patients with Cardiovascular-Kidney-Metabolic Syndrome: A Real-World Study.

|May 14, 2025
Extra Virgin Olive Oil Phenolic Compounds: Modulating Mitochondrial Function and Protecting Against Chronic Diseases-A Narrative Review.

María Ángeles Silva-Soto, Paloma Carrillo-Fernández, Estefanía T Saez Lancellotti

|Feb 17, 2022
Reply to: Comment on: Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure.

Luis M Pérez-Belmonte, José P Miramontes-González, Julio Osuna-Sánchez

|Nov 29, 2021
Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure.

Luis M Pérez-Belmonte, Jaime Sanz-Cánovas, Mercedes Millán-Gómez

|Aug 27, 2021
Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure.

Luis M Pérez-Belmonte, Michele Ricci, Jaime Sanz-Cánovas

Pageof 2

Frequent Collaborators

5 joint publications

María-Rosa Bernal-López

5 joint publications

Ricardo Gomez-Huelgas

4 joint publications

María Dolores López-Carmona

2 joint publications

Jaime Sanz-Cánovas